Journal of Cancer Research
- ISSN: 2578-3726
Dito Anurogo, Nur Arfian, Woro Danurwendo, Abdurahman Laqif, Sofia Mubarika and Mustofa
Background: Ischemia/reperfusion (I/R) is a key factor in the pathophysiology of acute kidney injury (AKI), which can lead to chronic renal failure. The annual incidence of AKI is approximately 2000-3000 patients per million of the population. Despite various approaches attempted to combat AKI, both the general public and scientists remain unsatisfied. Conditioned medium from mesenchymal stem cells (CM-MSCs), containing growth factors, holds potential as an alternative therapy for AKI.
Objective: This study aimed to investigate whether CM-MSCs could reduce serum creatinine levels, repair injured tubular cells, and enhance proliferation of tubular epithelial cells in a mice model of renal I/R.
Methods: A pure experimental study was conducted using a completely randomized design with 20 Swiss male mice, aged 3-4 months and weighing 25-35 grams, classified into 4 groups, each comprising 5 mice. Periodic Acid Schiff (PAS) staining was employed to assess renal tubular injury, and tubular injury scores were recorded. Immunohistochemical staining with PCNA antibody was used to observe cell proliferation. Statistical analysis was performed using STATA 12.
Results: The statistical analysis revealed that treatment with 0.1 cc and 0.2 cc CM-MSCs did not significantly decrease serum creatinine levels when compared to the IR group. However, treatment with 0.1 cc and 0.2 cc CM-MSCs resulted in a significant reduction in tubular epithelial cell injury scores when compared to both the IR and SO groups. Conversely, treatment with 0.1 cc and 0.2 cc CM-MSCs did not significantly decrease the proliferation of renal tubular epithelial cells when compared to the IR group.
Conclusion: The administration of CM-MSCs in the mice model had a significant impact on serum creatinine levels, tubular epithelial cell injury, and proliferation of renal tubular epithelial cells (demonstrated by PCNA expression) during renal IRI. CM-MSCs show potential as an alternative therapy for AKI, although further comprehensive and multiperspective research is necessary to advance their development in regenerative medicine